These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Synthesis of potent and selective dopamine D(4) antagonists as candidate radioligands. Huang Y; Kegeles LS; Bae S; Hwang D; Roth BL; Savage JE; Laruelle M Bioorg Med Chem Lett; 2001 Jun; 11(11):1375-7. PubMed ID: 11378358 [TBL] [Abstract][Full Text] [Related]
25. Sensitization of endogenous and recombinant adenylate cyclase by activation of D2 dopamine receptors. Watts VJ; Neve KA Mol Pharmacol; 1996 Oct; 50(4):966-76. PubMed ID: 8863843 [TBL] [Abstract][Full Text] [Related]
26. Dopamine D3 and D4 receptor antagonists: synthesis and structure--activity relationships of (S)-(+)-N-(1-Benzyl-3-pyrrolidinyl)-5-chloro-4- [(cyclopropylcarbonyl) amino]-2-methoxybenzamide (YM-43611) and related compounds. Ohmori J; Maeno K; Hidaka K; Nakato K; Matsumoto M; Tada S; Hattori H; Sakamoto S; Tsukamoto S; Usuda S; Mase T J Med Chem; 1996 Jul; 39(14):2764-72. PubMed ID: 8709107 [TBL] [Abstract][Full Text] [Related]
27. Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: 1. Activation of postsynaptic D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin secretion and catalepsy. Millan MJ; Peglion JL; Vian J; Rivet JM; Brocco M; Gobert A; Newman-Tancredi A; Dacquet C; Bervoets K; Girardon S J Pharmacol Exp Ther; 1995 Nov; 275(2):885-98. PubMed ID: 7473180 [TBL] [Abstract][Full Text] [Related]
28. Dopamine D3 receptor selective ligands with varying intrinsic efficacies at adenylyl cyclase inhibition and mitogenic signaling pathways. Taylor M; Grundt P; Griffin SA; Newman AH; Luedtke RR Synapse; 2010 Mar; 64(3):251-66. PubMed ID: 19924694 [TBL] [Abstract][Full Text] [Related]
29. A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194. Audinot V; Newman-Tancredi A; Gobert A; Rivet JM; Brocco M; Lejeune F; Gluck L; Desposte I; Bervoets K; Dekeyne A; Millan MJ J Pharmacol Exp Ther; 1998 Oct; 287(1):187-97. PubMed ID: 9765337 [TBL] [Abstract][Full Text] [Related]
30. Dopamine D4 versus D2 receptor selectivity of dopamine receptor antagonists: possible therapeutic implications. Lahti RA; Evans DL; Stratman NC; Figur LM Eur J Pharmacol; 1993 Jun; 236(3):483-6. PubMed ID: 8102973 [TBL] [Abstract][Full Text] [Related]
31. I. NGD 94-1: identification of a novel, high-affinity antagonist at the human dopamine D4 receptor. Tallman JF; Primus RJ; Brodbeck R; Cornfield L; Meade R; Woodruff K; Ross P; Thurkauf A; Gallager DW J Pharmacol Exp Ther; 1997 Aug; 282(2):1011-9. PubMed ID: 9262370 [TBL] [Abstract][Full Text] [Related]
32. Synthesis, in silico, and in vitro studies of novel dopamine D Elek M; Djokovic N; Frank A; Oljacic S; Zivkovic A; Nikolic K; Stark H Arch Pharm (Weinheim); 2021 Jun; 354(6):e2000486. PubMed ID: 33615541 [TBL] [Abstract][Full Text] [Related]
33. Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents. Sautel F; Griffon N; Sokoloff P; Schwartz JC; Launay C; Simon P; Costentin J; Schoenfelder A; Garrido F; Mann A J Pharmacol Exp Ther; 1995 Dec; 275(3):1239-46. PubMed ID: 8531087 [TBL] [Abstract][Full Text] [Related]
34. Characterisation of a chimeric hD3/D2 dopamine receptor expressed in CHO cells. McAllister G; Knowles MR; Patel S; Marwood R; Emms F; Seabrook GR; Graziano M; Borkowski D; Hey PJ; Freedman SB FEBS Lett; 1993 Jun; 324(1):81-6. PubMed ID: 8099332 [TBL] [Abstract][Full Text] [Related]
35. Synthesis and quantitative structure-activity relationships of N-(1-benzylpiperidin-4-yl)phenylacetamides and related analogues as potent and selective sigma1 receptor ligands. Huang Y; Hammond PS; Whirrett BR; Kuhner RJ; Wu L; Childers SR; Mach RH J Med Chem; 1998 Jun; 41(13):2361-70. PubMed ID: 9632369 [TBL] [Abstract][Full Text] [Related]
36. Examining the Effects of Sodium Ions on the Binding of Antagonists to Dopamine D2 and D3 Receptors. Newton CL; Wood MD; Strange PG PLoS One; 2016; 11(7):e0158808. PubMed ID: 27379794 [TBL] [Abstract][Full Text] [Related]
37. 6-(4-Benzylpiperazin-1-yl)benzodioxanes as selective ligands at cloned primate dopamine D(4) receptors. Hodgetts KJ; Kieltyka A; Brodbeck R; Tran JN; Wasley JW; Thurkauf A Bioorg Med Chem; 2001 Dec; 9(12):3207-13. PubMed ID: 11711296 [TBL] [Abstract][Full Text] [Related]
38. S 18126 ([2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl]), a potent, selective and competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2, 3b]pyridine) and raclopride. Millan MJ; Newman-Tancredi A; Brocco M; Gobert A; Lejeune F; Audinot V; Rivet JM; Schreiber R; Dekeyne A; Spedding M; Nicolas JP; Peglion JL J Pharmacol Exp Ther; 1998 Oct; 287(1):167-86. PubMed ID: 9765336 [TBL] [Abstract][Full Text] [Related]
39. Sigma1 and dopamine D2 receptor occupancy in the mouse brain after a single administration of haloperidol and two dopamine D2-like receptor ligands. Ishiwata K; Kawamura K; Kobayashi T; Matsuno K Nucl Med Biol; 2003 May; 30(4):429-34. PubMed ID: 12767400 [TBL] [Abstract][Full Text] [Related]
40. Affinity for dopamine D2, D3, and D4 receptors of 2-aminotetralins. Relevance of D2 agonist binding for determination of receptor subtype selectivity. van Vliet LA; Tepper PG; Dijkstra D; Damsma G; Wikström H; Pugsley TA; Akunne HC; Heffner TG; Glase SA; Wise LD J Med Chem; 1996 Oct; 39(21):4233-7. PubMed ID: 8863800 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]